Prospective Observation Cohort Study of Patients with Metastatic HER-2+ Breast Cancer At Risk of Cardiac Toxicity

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.

Study ID: 3394
NCT Number: NCT03418961
Principal Investigator: Puja Nistala, MD
Department: Medicine-Hematology & Oncology
Eligibility: Both men and women 18 years old to 100 years old. Does not accept healthy volunteers.

For questions about this study, please contact:

CancerClinicalTrials@health.missouri.edu